alpha tau medical ltd - DRTS

DRTS

Close Chg Chg %
7.32 -0.08 -1.09%

Closed Market

7.24

-0.08 (1.09%)

Volume: 99.65K

Last Updated:

Feb 19, 2026, 4:00 PM EDT

Company Overview: alpha tau medical ltd - DRTS

DRTS Key Data

Open

$7.30

Day Range

7.07 - 7.32

52 Week Range

2.30 - 7.89

Market Cap

$614.75M

Shares Outstanding

85.26M

Public Float

57.38M

Beta

1.05

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.52

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

332.68K

 

DRTS Performance

1 Week
 
1.53%
 
1 Month
 
2.81%
 
3 Months
 
91.62%
 
1 Year
 
173.13%
 
5 Years
 
N/A
 

DRTS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About alpha tau medical ltd - DRTS

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

DRTS At a Glance

Alpha Tau Medical Ltd.
Kiryat HaMada Street 5
Jerusalem, Jerusalem 9777605
Phone 972-3-577-4115 Revenue 0.00
Industry Medical Specialties Net Income -31,750,000.00
Sector Health Technology Employees 112
Fiscal Year-end 12 / 2025
View SEC Filings

DRTS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.482
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.764
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.075

DRTS Efficiency

Revenue/Employee N/A
Income Per Employee -283,482.143
Receivables Turnover N/A
Total Asset Turnover N/A

DRTS Liquidity

Current Ratio 7.404
Quick Ratio 7.404
Cash Ratio 7.246

DRTS Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -32.801
Return on Equity -43.156
Return on Total Capital -42.22
Return on Invested Capital -37.161

DRTS Capital Structure

Total Debt to Total Equity 20.004
Total Debt to Total Capital 16.67
Total Debt to Total Assets 14.542
Long-Term Debt to Equity 18.391
Long-Term Debt to Total Capital 15.325
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Alpha Tau Medical Ltd - DRTS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
776.00K 979.00K 1.07M 1.10M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
776.00K 979.00K 1.07M 1.10M
Depreciation
776.00K 979.00K 1.07M 1.10M
Amortization of Intangibles
- - - -
-
COGS Growth
- +26.16% +9.70% +2.61%
Gross Income
(776.00K) (979.00K) (1.07M) (1.10M)
Gross Income Growth
- -26.16% -9.70% -2.61%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
13.01M 31.16M 34.61M 34.94M
Research & Development
10.67M 20.89M 26.42M 27.02M
Other SG&A
2.34M 10.27M 8.18M 7.92M
SGA Growth
+947,061.57% +139.41% +11.07% +0.97%
Other Operating Expense
- - - -
-
Unusual Expense
- 3.79M (2.03M) (259.00K)
EBIT after Unusual Expense
(13.79M) (35.92M) (33.65M) (35.78M)
Non Operating Income/Expense
(201.00K) 2.20M 4.54M 4.38M
Non-Operating Interest Income
211.00K 1.79M 4.75M 4.28M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
13.27M 21.00K 39.00K 344.00K
Interest Expense Growth
- -99.84% +85.71% +782.05%
Gross Interest Expense
13.27M 21.00K 39.00K 344.00K
Interest Capitalized
- - - -
-
Pretax Income
(27.26M) (33.74M) (29.14M) (31.74M)
Pretax Income Growth
-1,984,179.48% -23.76% +13.64% -8.93%
Pretax Margin
- - - -
-
Income Tax
7.00K 20.00K 16.00K 6.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
7.00K 20.00K 16.00K 6.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(27.27M) (33.76M) (29.16M) (31.75M)
Minority Interest Expense
- - - -
-
Net Income
(27.27M) (33.76M) (29.16M) (31.75M)
Net Income Growth
-1,984,688.94% -23.80% +13.64% -8.89%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(27.27M) (33.76M) (29.16M) (31.75M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(27.27M) (33.76M) (29.16M) (31.75M)
EPS (Basic)
-0.6729 -0.5314 -0.4203 -0.454
EPS (Basic) Growth
- +21.03% +20.91% -8.02%
Basic Shares Outstanding
40.53M 63.53M 69.38M 69.93M
EPS (Diluted)
-0.6729 -0.5314 -0.4203 -0.454
EPS (Diluted) Growth
- +21.03% +20.91% -8.02%
Diluted Shares Outstanding
40.53M 63.53M 69.38M 69.93M
EBITDA
(13.01M) (31.16M) (34.61M) (34.94M)
EBITDA Growth
-949,827.01% -139.41% -11.07% -0.97%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 8.667
Number of Ratings 4 Current Quarters Estimate -0.12
FY Report Date 03 / 2026 Current Year's Estimate -0.481
Last Quarter’s Earnings -0.122 Median PE on CY Estimate N/A
Year Ago Earnings -0.513 Next Fiscal Year Estimate -0.368
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 4 3
Mean Estimate -0.12 -0.12 -0.48 -0.37
High Estimates -0.11 -0.11 -0.45 -0.28
Low Estimate -0.13 -0.13 -0.50 -0.42
Coefficient of Variance -8.33 -8.33 -4.50 -20.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Alpha Tau Medical Ltd in the News